Global assessment of the coagulation status in type 2 diabetes mellitus using rotation thromboelastography

Blood Coagulation and Fibrinolysis

Volumn 17, Issue 7, 2006, Pages 545-549

  Yürekli, Banu Pinar Sarer ^a   Özcebe, Osman Ilhami ^b   Kirazli, Serafettin ^b   Gürlek, Alper ^a,c  

^a HACETTEPE UNIVERSITY   (Turkey)

^b Division of Hematology   (Turkey)

^c Division of Endocrinology   (Turkey)

Author keywords

Fibrinolysis; Thromboelastography; Thrombosis; Type 2 diabetes mellitus

Indexed keywords

FIBRINOGEN; PROCOAGULANT;

ADULT; ARTICLE; BLOOD CLOTTING DISORDER; BLOOD CLOTTING TIME; BODY MASS; CLINICAL ASSESSMENT; CLOT FORMATION TIME; CONTROLLED STUDY; DIABETIC ANGIOPATHY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM CLOT FIRMNESS; NON INSULIN DEPENDENT DIABETES MELLITUS; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; ROTATIONAL THROMBOELASTOGRAPHY; THROMBIN TIME; THROMBOCYTE COUNT; THROMBOELASTOGRAPHY;

BLOOD COAGULATION; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; MALE; MIDDLE AGED; REFERENCE VALUES; THROMBELASTOGRAPHY; TIME FACTORS;

EID: 33748946946     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mbc.0000245292.34150.df     Document Type: Article

References (15)

1. Feskens EJ, Kromhout D. Glucose tolerance and the risk of cardiovascular disease: the Zutphen study. J Clin Epidemiol 1992; 45:1327-1334.
2. Egeberg O. The blood coagulability in diabetic patients. Scand J Clin Lab Invest 1963; 15:533-538.
3. Colwell JA. Vascular thrombosis in type II diabetes mellitus. Diabetes 1993; 42:8-11.
4. Small M, Kluft C, MacCuish AC, Lowe GDD. Tissue plasminogen actiavtor inhibition in diabetes mellitus. Diabetes Care 1989; 12:655-658.
5. Panahloo A, Yudkin JS. Diminished fibrinolysis in diabetes mellitus and its implication for diabetic vascular disease. J Cardiovasc Res 1997; 4:91-99.
6. Mallett JV, Cox JA. Thromboelastography. Br J Anaesth 1992; 69:307-313.
7. Srinivasa V, Gilbertson IL, Bhavani-Shankar K. Thromboelastography. Where is it and where is it heading? Int Anesthesiol Clin 2001; 39:35-49.
8. Entholzner EK, Mielke LL, Calatzis AN, Feyh J, Hipp R, Hargasser SR. Coagulation effects of a recently developed hydroxy ethyl starch (HES 130/0,4) compared to hydroxyethyl starches with higher molecular weight. Acta Anaesthesiol 2000; 44:1116-1121.
9. Haisch G, Boldt J, Krebs C, Kumle B, Suttner S, Schulz A. The influence of intravascular volume therapy with a new hydroxyethyl starch preparation (6% HES 130(0.4)) on coagulation in patients undergoing major abdominal surgery. Anesth Analg 2001; 92:565-571.
10. Fries D, Innerhofer P, Klingler A, Berresheim U, Mittermayr M, Calatzis A, Schobersberger W. The effect of combined administration of colloids and lactated Ringer's solution on the coagulation analysis (ROTEM®). Anesth Analg 2002; 4:1280-1287.
11. Dunn EJ, Grant PJ. Type 2 diabetes: an atherothrombotic syndrome. Curr Mol Med 2005; 5:323-332.
12. Carr ME. Diabetes mellitus: a hypercoagulable state. J Diabetes Complicat 2001; 15:44-54.
13. Colhoun HM, Zito F, Norman NC, Rubens MB, Fuller JH, Humphries SE. Activated factor XII levels and factor XII 46 C>T genotype in relation to coronary artery calcification in patients with type 1 diabetes and healthy subjects. Atherosclerosis 2002; 163:363-369.
14. Patrassi GM, Vettor R, Padovan D, Girolani A. Contact phase of anticoagulation in diabetes mellitus. Eur J Clin Invest 1982; 12:307-311.
15. Burke GW, Ciancio G, Figueiro J, Buigas R, Olson L, Roth D, et al. Hypercoagulable state associated with kidney-pancreas transplantation. Thromboelastogram-directed anti-coagulation and implications for future therapy. Clin Transplant 2004; 18:423-428.